Drug Profile
Research programme: ligase-targeted therapies - Celgene
Alternative Names: CC 125007; CC 12507; E2 ligase inhibitorLatest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Ubiquitin-protein ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Cancer in USA
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 17 Dec 2017 Preclinical development for Cancer is ongoing in USA (NCT03374085)